Literature DB >> 2731182

Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer.

G Parrilli1, R V Iaffaioli, M Martorano, R Cuomo, S Tafuto, M G Zampino, G Budillon, A R Bianco.   

Abstract

Although cytotoxic chemotherapy for human cancer has been reported to induce alterations in intestinal permeability, its effects on the absorptive process are still controversial. We have studied mediated and nonmediated absorption in 10 patients with metastatic breast cancer before and after treatment with Adriamycin by the use of specific test sugars given orally and their subsequent urinary recovery, as measured by chromatography. Mediated absorption was investigated by the use of D-xylose and 3-O-methylglucose, while lactulose and L-rhamnose were used to study nonmediated permeation. Lactulose is considered a marker of unmediated paracellular (tight junction) permeation, while L-rhamnose explores passage across cell membranes. The test was performed on patients before and on the second and the eighth days after Adriamycin administration, and only once in 22 age-matched healthy women. Under basal conditions, as well as 2 and 8 days after chemotherapy, D-xylose and 3-O-methylglucose absorption was 35% lower in patients than in controls (P less than 0.001). Lactulose absorption was significantly higher in patients than in controls under basal conditions (P less than 0.001); it reached levels three times higher the second day after chemotherapy, and returned to basal levels by the eighth day. The data suggest an early reversible effect of Adriamycin on cellular tight junctions with resulting increased permeabilization. This effect seems of a toxic nature rather than due to increased cell loss. It is interesting that both nonmediated absorption and mediated absorption were already altered before chemotherapy in cancer patients, suggesting a preexisting functional damage of the intestine. The significance of this alteration as a potential mechanism of cancer cachexia is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731182

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Cognitive problems of breast cancer survivors on proton pump inhibitors.

Authors:  Annelise A Madison; Alex Woody; Brittney Bailey; Maryam B Lustberg; Bhuvaneswari Ramaswamy; Robert Wesolowski; Nicole Williams; Raquel Reinbolt; Jeffrey B VanDeusen; Sagar Sardesai; William B Malarkey; Janice K Kiecolt-Glaser
Journal:  J Cancer Surviv       Date:  2020-01-13       Impact factor: 4.442

2.  Measuring mucosal damage induced by cytotoxic therapy.

Authors:  N M A Blijlevens; B van't Land; J P Donnelly; L M'Rabet; B E de Pauw
Journal:  Support Care Cancer       Date:  2004-01-30       Impact factor: 3.603

3.  Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis.

Authors:  B A Carneiro-Filho; I P F Lima; D H Araujo; M C Cavalcante; G H P Carvalho; G A C Brito; V Lima; S M N Monteiro; F N Santos; R A Ribeiro; A A M Lima
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

4.  A More Robust Gut Microbiota in Calorie-Restricted Mice Is Associated with Attenuated Intestinal Injury Caused by the Chemotherapy Drug Cyclophosphamide.

Authors:  Tao Liu; Yanqiu Wu; Linghua Wang; Xiaoyan Pang; Liping Zhao; Huijuan Yuan; Chenhong Zhang
Journal:  mBio       Date:  2019-03-12       Impact factor: 7.867

Review 5.  Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview.

Authors:  N M Blijlevens; J P Donnelly; B E De Pauw
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

6.  Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum.

Authors:  Bohuslav Melichar; Radomír Hyspler; Emanuela Dragounová; Josef Dvorák; Hana Kalábová; Alena Tichá
Journal:  BMC Cancer       Date:  2007-08-09       Impact factor: 4.430

7.  Transforming Growth Factor-beta2 protects the small intestine during methotrexate treatment in rats possibly by reducing stem cell cycling.

Authors:  B van't Land; H P Meijer; J Frerichs; M Koetsier; D Jager; R L Smeets; L M'Rabet; M Hoijer
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.